Evidence map›Paper›PMID 29936468›Full record

ArticleIn vivo (Athens, Greece)

Impressive Long-term Response with Pertuzumab and Trastuzumab in HER2-positive Breast Cancer with Brain Metastasis.

Michelangelo Russillo, Gianluigi Ferretti, Antonello Vidiri, Simona Gasparro, Francesco Cognetti, Domenica Pellegrini, Alessandra Fabi

Open access · diamondAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Michelangelo RussilloDivision of Medical Oncology 1, Regina Elena National Cancer Institute, Rome, Italy.
Gianluigi FerrettiDivision of Medical Oncology 1, Regina Elena National Cancer Institute, Rome, Italy.
Antonello VidiriDepartment of Neuroscience, Imaging Diagnostic, Regina Elena National Cancer Institute, Rome, Italy.
Simona GasparroDivision of Medical Oncology 1, Regina Elena National Cancer Institute, Rome, Italy.
Francesco CognettiDivision of Medical Oncology 1, Regina Elena National Cancer Institute, Rome, Italy.
Domenica PellegriniDivision of Medical Oncology 1, Regina Elena National Cancer Institute, Rome, Italy.
Alessandra FabiDivision of Medical Oncology 1, Regina Elena National Cancer Institute, Rome, Italy alessandra.fabi@virgilio.it.
National Cancer Institute · MY

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This is a case report of a 40-year-old woman who, after conservative breast cancer treatment, developed a HER2 positive solitary brain metastasis in the left temporal lobe, without extracranial disease. She underwent surgery resection followed by stereotactic radiotherapy and, because of early brain progression, she was submitted to the first line therapy with pertuzumab, trastuzumab and weekly paclitaxel. After six months of treatment, a brain magnetic resonance imaging revealed a complete disappearance of brain recurrence, which persisted for more than 24 months.

Indexed as

AdultAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsBrainBrain NeoplasmsBreast NeoplasmsCombined Modality TherapyErb-b2 Receptor Tyrosine KinasesFemaleHumansNeoplasm MetastasisNeoplasm Recurrence, LocalRadiosurgeryTrastuzumabAntibodies, Monoclonal, HumanizedERBB2 protein, humanErb-b2 Receptor Tyrosine KinasespertuzumabTrastuzumabbrain metastasismetastatic breast cancerPertuzumab

Identifiers

PMID29936468
PMCPMC6117761
OpenAlexW2809809976

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.